Oral IDH1 Inhibitor Ivosidenib Holds Rare Liver Cancer at Bay for 35 Months in Case Report
A case report documents 35 months of oral ivosidenib therapy with partial remission and no adverse events in a man ...
Tag: IDH1 mutation
POPULAR NEWS
-
Systematic review maps end-of-life psychosocial and spiritual needs in physical disability
-
Text Message Campaign Reached Only a Third of Patients Overdue for Colorectal Cancer Screening
-
FOXO1 Emerges as Candidate Regulator and Biomarker in Hip Dysplasia
-
Regulators, developers and clinicians in Shenzhen voice concerns over medical AI governance